Anti-ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with ebola virus disease by Brown, J.F. et al.
Anti–Ebola Virus Antibody Levels in Convalescent Plasma 
and Viral Load After Plasma Infusion in Patients With 
Ebola Virus Disease
Jerry F. Brown,1,a John M. Dye,2,a Sam Tozay,1 Gertrude Jeh-Mulbah,1 David A. Wohl,3 William A. Fischer 2nd,3 Coleen K. Cunningham,4  
Kathleen Rowe,5 Peter Zacharias,6 James van Hasselt,6 David A. Norwood,2 Nathan M. Thielman,4 Samantha E. Zak,2 and David L. Hoover7
1Eternal Love Winning Africa Hospital, Paynesville, Liberia; 2US Army Medical Research Institute of Infectious Disease, Frederick, Maryland; 3University of North Carolina 
School of Medicine, Chapel Hill;  4Duke University School of Medicine, Durham, North Carolina; 5Blood Centers of America, West Warwick, Rhode Island; 6Safe Blood for Africa 
Foundation, Washington, District of Columbia; and 7Clinical Research Management, Inc, Hinckley, OhioXX
Background. Ebola virus (EBOV) neutralizing antibody in plasma may reduce viral load following administration of plasma to 
patients with Ebola virus disease (EVD), but measurement of these antibodies is complex.
Methods. Anti-EBOV antibody was measured by 2 neutralization and 2 enzyme-linked immunosorbent assays (ELISAs) in 
convalescent plasma (ECP) from 100 EVD survivor donors in Liberia. Viral load was assessed repetitively in patients with EVD 
participating in a clinical trial of enhanced standard of care plus ECP.
Results. All 4 anti-EBOV assays were highly concordant for detection of EBOV antibody. Antibodies were not detected in 
plasma specimens obtained from 15 of 100 donors, including 7 with documented EBOV-positive reverse-transcription polymerase 
chain reaction during EVD. Viral load was reduced following each dose in the 2 clinical trial participants who received ECP with 
higher antibody levels but not in the 2 who received ECP with lower antibody levels.
Conclusions. Recovery from EVD can occur with absence of detectable anti-EBOV antibody several months after disease onset. 
ELISAs may be useful to select ECP donors or identify ECP units that contain neutralizing antibody. ECP with higher anti-EBOV 
antibody levels may have greater effect on EBOV load—an observation that requires further investigation.
Clinical Trials Registration. NCT02333578.
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Ebola virus disease (EVD) produces rapidly progressive mul-
tiorgan system failure and is fatal in 40%–90% of patients. The 
survival advantage of an early humoral immune response to 
Ebola virus (EBOV) was documented during the 1996 Gabon 
outbreak, in which survivors manifested increasing levels of im-
munoglobulin G (IgG) against virus nucleoprotein [1]; in con-
trast, EBOV-specific IgG was not detected in fatal cases. This 
recognition of a correlation between humoral response and sur-
vival has led to attempts to treat acute EVD with whole blood or 
plasma collected from survivors—a precedent established with 
pathogen-specific immunoglobulin therapy for hepatitis B virus 
infection [2], influenza [3, 4], Argentine hemorrhagic fever [5], 
and severe acute respiratory syndrome [6].
Anecdotal reports of EVD patients treated with convalescent 
whole blood from the 1995 Kikwit Ebola outbreak suggested 
improved survival compared with untreated patients [7]. This 
finding, however, was confounded by the use of historical 
controls and a higher level of supportive care among those 
transfused. We collected Ebola convalescent plasma (ECP) by 
apheresis from EVD survivors in Liberia in 2014–2015, meas-
ured anti-EBOV antibodies using 4 different assays, and exam-
ined the virologic and clinical outcomes of acute EVD patients 
treated with ECP or enhanced standard of care in a controlled 
clinical trial.
METHODS
ECP was collected from EVD survivors and administered 
to EVD patients at the Eternal Love Winning Africa (ELWA) 
Hospital and the ELWA Ebola Treatment Unit-2 (ELWA-2) in 
Paynesville, Liberia. Clinical protocols for plasma collection, 
specimen analysis, and the treatment trial (ClinicalTrials.gov 
NCT02333578) sponsored by Clinical Research Management, 
Inc, were reviewed and approved by the University of Liberia 
Pacific Institute for Research and Evaluation; the Liberia 
Medicines and Health Products Regulatory Authority; and the 
institutional review boards of the University of North Carolina, 
Duke University, and the US Army Medical Research and 
Materiel Command. All ECP donors and clinical trial par-
ticipants provided written, informed consent. Studies were 
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conducted in accordance with the Declaration of Helsinki, 
Good Clinical Practices, and applicable laws and regulations.
Collection of ECP and Analysis of Anti-EBOV Antibodies
Collection of ECP
As previously described [8], ECP was collected by apheresis 
from EVD survivor donors with Ebola treatment unit dis-
charge certificates who met World Health Organization–rec-
ommended criteria for blood donation. ECP (650  mL) was 
treated with amotosalen and illuminated with ultraviolet light 
(INTERCEPT, Cerus) prior to distribution into six 100-mL 
bags. Bags of ECP were frozen within 6 hours of collection 
and stored below –18°C until thawed to ambient temperature 
immediately prior to infusion.
Collection of Blood for Antibody Levels
Blood for determination of anti-EBOV antibody levels was 
collected in ethylenediaminetetraacetic acid (EDTA) tubes at 
screening and ECP donation visits. Specimen tubes were pro-
cessed within 24 hours at the Liberian Institute of Biomedical 
Research (LIBR), where they were centrifuged, and plasma was 
divided into 0.5-mL aliquots, which were frozen and main-
tained at –20°C until analysis for anti-EBOV antibody levels at 
the US Army Medical Research Institute of Infectious Diseases.
Quantitative ELISAs
Survivor plasma samples, naive human serum (negative con-
trol), and EBOV convalescent nonhuman primate (NHP) 
serum (positive control) were serially diluted and added to 
plates coated with either recombinant EBOV glycoprotein 
(GP) or irradiated whole EBOV antigen. Reference standard 
was serially diluted in accordance with protocols specific for 
each antigen of interest. Following room temperature incuba-
tion, plates were washed and incubated with horseradish per-
oxidase–labeled anti-human IgG secondary antibody. Again, 
plates were washed following room temperature incubation and 
2,2′-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) substrate 
was added. Absorbance values were measured at 405 nm using 
a plate reader. The absorbance value of each test sample dilu-
tion that fell within the acceptable range (based on coefficient 
of variation and percentage recovery) of the reference standard 
curve was used to calculate the amount (units/mL) of EBOV 
GP- or EBOV-specific antibody. Cutoff values for each ELISA 
were defined as the mean + 3 times the standard deviation (SD) 
titer of negative control serum collected from uninfected indi-
viduals in Uganda.
Neutralization Assays
Survivor plasma samples and naive human serum were diluted 
1:10, 1:20, and 1:40 in cell culture media, in duplicate. EBOV-
specific monoclonal antibody KZ52 was used as the positive con-
trol. Diluted test specimens and controls were mixed with EBOV 
and incubated at 37°C for 1 hour before adding to Vero E6 cells. 
Unbound virus was washed away after a further 1-hour incubation. 
For the microneutralization assay (MNA), Vero growth media was 
added back to the cells. Cells were fixed 48 hours postinfection and 
infected cells were detected using EBOV-specific monoclonal anti-
body and fluorescently labeled secondary antibodies. The percent-
age of infected cells was determined using an Operetta high-content 
imaging system and Harmonia software. Results were expressed as 
MNA50 titer, the highest plasma dilution that neutralized ≥50% of 
virus. For the 50% plaque reduction neutralization test (PRNT50), 
after removal of unbound virus, Vero cells were overlaid with agar-
ose. Plaque reduction was assessed as previously described [9] and 
results expressed as PRNT50 titer; percentage neutralization at each 
plasma dilution was also recorded.
Clinical Trial of ECP
Objectives
The primary trial objective was correlation of anti-EBOV IgG 
and neutralization titers in ECP with kinetics of plasma viral 
load in ECP-treated participants. Secondary objectives were 
to describe kinetics of plasma viral load in participants treated 
with and without ECP and compare kinetics of viral load 
between groups; compare survival up to time of hospital dis-
charge of participants treated for EVD with and without ECP; 
and assess safety of treatment with and without ECP.
Participants
Eligible participants were patients at ELWA-2 Ebola Treatment 
Unit (ETU) at least 18  years of age with EVD confirmed by 
RT-PCR who had been admitted to the confirmed section of the 
ETU no more than 48 hours prior to enrollment, had adequate 
vascular access, and were able to provide informed consent or 
had a family member who could consent for them.
Treatment
Participants were allocated to receive either enhanced standard 
of care alone (control group) or enhanced standard of care plus 
ECP (ECP group). Enhanced standard of care included aggres-
sive intravenous hydration and electrolyte replacement guided 
by handheld point-of-care diagnostic testing (iSTAT, Abbott 
Diagnostics). In addition, participants routinely received pro-
phylactic ceftriaxone intravenously, oral antimalarial therapy 
with chloroquine or artemether/lumefantrine, and oral sele-
nium as a nutritional supplement.
Following enrollment, participants were assigned, in order of 
ETU admission, to the ECP group if ABO-compatible ECP was 
available or, if ABO-compatible ECP was not available, to the 
control group. Participants in the ECP group received 200 mL 
of ECP intravenously (100 mL from 1 donor followed immedi-
ately by 100 mL from another donor) per dose. This dose could 
be repeated every 48 hours using the same lots of ECP used for 
the first dose for up to 3 doses unless participants were con-
sidered by the principal investigator to have improved and had 
been afebrile for at least 36 hours.
Assessments
Participants in both groups were followed with frequent vital 
signs and assessment of adverse events. Safety laboratory tests 
were performed at least every other day and more often if clin-
ically indicated and feasible. Blood was collected into EDTA 
tubes for viral load at enrollment, immediately prior to and 4 
hours after completion of each 200-mL ECP treatment, and 
daily on noninfusion days for the ECP group; control group 
specimens were collected every 48 hours.
Plasma viral load was measured at LIBR using the 
Department of Defense EZ1 real-time RT-PCR assay [10] and 
reported as cycle threshold (Ct). Ct values were converted to 
log10 genomic equivalent (GE)/mL by a formula derived from 
the assay validation: log10 GE/mL = log10 800 + (Ct – 41.16) / –3.36, 
where 800  =  sample dilution factor, 41.16  =  y-intercept, and 
–3.36 = slope of Ct (y) vs log10 GE (x).
Statistical Methods
Laboratory values were summarized by descriptive statistics 
(mean, median, and SD). Between-group differences were 
assessed by Fisher exact test or t test. Pearson correlation was 
performed on ELISA and neutralization results. EBOV GP 
ELISA results below the limit of detection were assigned a value 
of 0.001 U, the lowest measured value in the assay. If ELISA tests 
were repeated (3 specimens), the median value was used for 
calculations. Sensitivity and specificity testing were performed 
using MedCalc (medcalc.org).
RESULTS
Anti-EBOV Antibody Titers in EVD Survivors
One hundred donor candidate survivors of EVD provided 190 
specimens. Of these, 9 specimens were unsatisfactory for test-
ing. All 4 antibody assays were conducted on 180 specimens; 1 
specimen was analyzed by all tests except the PRNT50. Table 1 
summarizes the results of all 4 tests from the first specimen col-
lected from each donor, and from the complete set of 180 speci-
mens. At least 2 specimens were obtained from 41 donors at times 
ranging from 53 to 252 days after their discharge from an ETU 
(Supplementary Table 1). In all but 1 donor, the PRNT50 serolog-
ical status (ie, ≥1:10 or <1:10) in the second sample remained un-
changed from the first specimen analyzed. In this donor (donor 
83, Supplementary Table 1), PRNT50 changed from 1:20 in the 
first specimen to <1:10 in a specimen collected 5 days later, while 
the ELISAs and the MNA50 remained positive, suggesting that the 
PRNT50 result of the second test was erroneous. Relative to the 
PRNT50 as the gold standard (including the potentially erroneous 
value noted above), both ELISAs were highly sensitive and spe-
cific (Table 1) and were highly concordant with each other for 
positive or negative serological status using cutoffs derived from 
normal serum specimens (P < .001, Fisher exact test). The quanti-
tative relationship (Pearson) between the 2 ELISA results for each 
specimen was highly significant but weak (P < .001 and r2 = 0.22), 
as were relationships between either ELISA and percentage neu-
tralization at each plasma dilution (1:10, 1:20, and ≥1:40) in 
PRNT50 (P < .001 for all comparisons, with r
2 = 0.15–0.21).
Figures 1A and 1B show the distributions of anti-EBOV GP 
and EBOV ELISA values from the first 100 specimens accord-
ing to their PRNT50 titer. ELISA-negative specimens clustered 
with specimens having PRNT50  <1:10, but there was no clear 
dose-response relationship between the ELISA values and the 
semiquantitative PRNT50 results in antibody-positive speci-
mens. Similar relationships were noted in the complete set of 
180 specimens (data not shown).
The MNA50 was also highly sensitive and specific for pre-
dicting positive and negative PRNT50 results (Table  1). Titers 
for the MNA50 tended to be lower than for the PRNT50 
Table 1. Performance Characteristics of Enzyme-Linked Immunosorbent Assays and 50% Microneutralization Assay Relative to 50% Plaque Reduction 
Neutralization Test
Initial Specimen (N = 100)
PRNT50 Positive (n = 85) PRNT50 Negative (n = 15)





MNA50 83 2 15 0 97.65 (91.76–99.71) 100.00 (78.20–100.00)
EBOV GP ELISA 85 0 15 0 100.00 (95.75–100.00) 100.00 (78.20–100.00)
EBOV ELISA 84 1 15 0 98.82 (93.62–99.97) 100.00 (78.20–100.00)
Complete Specimen Set (N = 180)
PRNT50 Positive (n = 141) PRNT50 Negative (n = 39)





MNA50 138 3 38 1 97.87 (93.91–99.56) 97.44 (86.52–99.94)
EBOV GP ELISA 141 0 37 2 100.00 (97.42–100.00) 94.87 (82.68–99.37)
EBOV ELISA 139 2 37 2 98.58 (94.97–99.83) 94.87 (82.68–99.37)
Abbreviations: CI, confidence interval; EBOV ELISA, enzyme-linked immunosorbent assay detecting whole Ebola virus; EBOV GP ELISA, enzyme-linked immunosorbent assay detecting 
Ebola virus glycoprotein; ELISA, enzyme-linked immunosorbent assay; MNA50, 50% microneutralization assay; PRNT50, 50% plaque reduction neutralization test.
(Supplementary Table 1). No consistent change in antibody lev-
els over time was observed in donors who provided repeated 
specimens (Supplementary Table 1).
For 7 of the antibody-negative donors, ETU records were 
available and included a laboratory report of a positive RT-PCR 
test for EBOV. These are identified as PCR-confirmed cases and 
listed separately from the nonconfirmed cases (Supplementary 
Table 1). IgM ELISAs on the initial IgG antibody–negative spec-
imens were negative and total IgG levels were normal (data not 
shown). Comparison of age, sex, vital signs, blood group, prev-
alence of positive tests for transfusion-transmitted infections, 
and hemoglobin levels showed no differences between PCR-
confirmed antibody-negative, all antibody-negative, and anti-
body-positive donors (data not shown). The PCR-confirmed 
antibody-negative donor group had a significantly shorter 
mean interval between ETU discharge date and first spec-
imen collection than did the antibody-negative nonconfirmed 
and antibody-positive groups (80, 157, and 144  days, respec-
tively), reflecting the better availability of records in the PCR-
confirmed group (Supplementary Table 1).
Clinical Trial Enrollment, Baseline Characteristics, and Treatment 
Allocation
The clinical trial, which began in December 2014, was designed 
to enroll 70 acute EVD participants. By March 2015, only 6 were 
enrolled as the incidence of EVD in Liberia dropped rapidly. 
Four participants (T1–T4) were assigned to the ECP group and 
2 (C1 and C2) to the control group.
Demographic and baseline clinical findings are shown in 
Supplementary Table  2. Typically, participants presented late 
in their course, often with diarrhea and conjunctival and gin-
gival bleeding. Clinical laboratory results, viral load at enroll-
ment, and survival outcome for each participant are shown in 
Supplementary Table 3. With the exception of participant T2, 
who had normal clinical laboratory values except for a creati-
nine level of 1.7 mg/dL, all participants had profound metabolic 
abnormalities on admission. Mean viral load at first determina-
tion was 8.0 ± 0.8 log10 GE (range, 6.8–8.9).
Clinical Course and Ebola Viral Load
We observed no adverse effects of treatment with ECP. ECP anti-
EBOV levels were not known during the trial; as a consequence, 
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Figure 1. A and B, Distributions of anti-Ebola virus (EBOV) and EBOV glycoprotein (GP) enzyme-linked immunosorbent assay (ELISA) values from the first 100 specimens 
according to their 50% plaque reduction neutralization test (PRNT50) titer. The first blood specimen collected from each plasma donor was assayed by immunoglobulin G (IgG) 
EBOV ELISA, IgG EBOV GP ELISA, and PRNT50. ELISA units per milliliter in each specimen were derived using a standard curve prepared with a reference antibody. Open circles 
depict ELISA results at each PRNT50 titer. Open horizontal bars denote median ELISA values. Dotted line indicates upper cutoff for negative ELISA values.
the antibody content of ECP varied. Two participants (T1 and 
T2) each received ECP units from 2 donors with EBOV-specific 
ELISA values near the median of all donor specimen values; 
MNA50 and PRNT50 were >1:40 (Table 2). Participants T1 and 
T2 each received 2 doses of ECP 48 hours apart; per protocol, 
neither received a third dose because they were considered to 
be improving at the scheduled 96-hour time point. On each 
occasion of ECP treatment, plasma viral load declined between 
the pre- and first postinfusion sampling point in both partic-
ipants (Figure  2). Participant T1’s viral load decreased 4-fold 
after the first dose and a further 31-fold after the second dose. 
Participant T2’s viral load decreased 2-fold following each dose, 
rebounded at 93 hours back to baseline, and slowly decreased 
thereafter. Despite severe clinical and laboratory manifestations 
of EVD (Supplementary Tables 2 and 3), Participant T1 gradu-
ally improved and survived. Participant T2 had less severe clin-
ical laboratory abnormalities on admission, but had a history 
of human immunodeficiency virus infection and hypertension 
(Supplementary Tables  2 and 3) and progressively increasing 
creatinine level. Participant T2 deteriorated clinically on day 6 
with pallor and epigastric tenderness, and died on day 10.
Participants T3 and T4 received ECP units containing much 
lower levels of Ebola-specific IgG and neutralizing activity than 
either of the ECP units provided to participants T1 and T2 
(Table 2). The viral load in participant T3, who received only 1 
infusion of ECP, did not change between the pre- and first post-
infusion sampling time points (Figure 2), but increased after-
ward approximately 2-fold prior to death on day 3. Participant 
T4’s viral load increased 2-fold after the first infusion and 
declined 2-fold after the second infusion (Figure 2), but then 
increased 4-fold. Participant T4 died before the scheduled 
96-hour third infusion.
No ABO-compatible ECP was available for control partici-
pants C1 and C2 (Figure 2). The viral load in participant C1, 
who survived, declined 2-fold over the first 48 hours and 645-
fold over the first 89 hours. The viral load in participant C2, who 
died on day 4, declined 4-fold over 43 hours. All 3 participants 
who survived for at least 8  days had detectable viral RNA in 
blood at least through day 7 (Figures 2 and 3).
DISCUSSION
We found a high concordance between 4 different assays (2 
ELISAs and 2 neutralization tests) for categorization of EVD 
survivors (candidate ECP donors) by anti-EBOV antibody 
status. Using PRNT50 results as a gold standard, the MNA50, 
EBOV ELISA, and EBOV GP ELISA were all highly sensi-
tive and specific tests. These data indicate that the ELISAs are 
excellent candidates for identification of EVD survivors who 
have neutralizing antibody, although the quantitative relation-
ship between percentage neutralization and ELISA values and 
between ELISAs was weak. Compared to neutralization assays, 
ELISAs for EBOV do not require virus culture, are much less 
labor-intensive, and can be conducted in diagnostic laborato-
ries with lower biosafety levels.
Given a previous report that failure to develop anti-EBOV 
antibodies predicted high mortality from EVD [1], the propor-
tion of participants with negative tests for anti-EBOV antibody 
led us to question whether these donor candidates were truly 
EVD survivors, even though selection required a history of 
EVD and a certificate of discharge from an ETU with a diag-
nosis of EVD. Although a positive RT-PCR result was found in 
ETU records for only 7 participants, most of the participants in 
this study had been personally cared for in the ELWA-2 ETU by 
1 of the authors (J. F. B.); their disease presentation and hospital 
course were believed at the time of treatment and discharge to 
be that of EVD and patients were not transferred to the con-
firmed section of the ETU unless a positive RT-PCR result had 
been received. It is possible, but unlikely, that the RT-PCR test 
results used for confirmatory diagnosis of EVD were erroneous. 
These findings suggest that between 7% and 15% of the ECP 
donors had severe EVD and survived, while failing to mount a 
specific humoral immune response to EBOV. The negative IgM 
ELISAs and normal concentrations of plasma IgG in the first 
specimen suggested that defective class switching or immuno-
globulin deficiency do not explain this failure. Negative tests for 
neutralizing antibody in 20% of 85 plasma units from 58 donors 
were observed in the Ebola-Tx trial [11]. Additional prospec-
tive studies should be conducted to examine the course of hu-
moral and cellular immune responses during acute EVD and to 
Table 2. Anti–Ebola Virus Antibodies in Infused Ebola Convalescent Plasma
Participants ECP Anti-EBOV GP IgG, U/mL Anti-EBOV IgG, U/mL MNA50 Titer PRNT50 Titer
T1 and T2 Donation Aa 12.57 1.39 >1:40 >1:40
Donation B 19.07 1.64 >1:40 >1:40
Mean unit 1b 15.82 1.52
T3 and T4 Donation C 8.36 0.28 1:10 1:40
Donation D 0.31 0.002 <1:10 <1:10
Mean unit 2 4.34 0.14
Abbreviations: EBOV GP, Ebola virus glycoprotein; ECP, Ebola convalescent plasma; IgG, immunoglobulin G; MNA50, 50% microneutralization assay; PRNT50, 50% plaque reduction neutral-
ization test; U/mL, laboratory units per milliliter of Ebola virus glycoprotein and Ebola virus enzyme-linked immunosorbent assays.
aDonations indicate specimens for antibody assay from donors obtained at the time of ECP donation.
bAt each dosing time point, clinical trial participants received 100 mL of ECP from each indicated donor one after the other, to make up a unit of ECP.
confirm the proportion of seronegative individuals among both 
survivors and fatalities.
The temporal relationships of ECP treatment and change 
in viral load in the 2 participants treated with ECP contain-
ing higher anti-EBOV levels suggest that ECP treatment may 
decrease viral load. Although the data are limited by the small 
number of enrolled participants and severity of disease in all 
enrollees, the results provide support for further assessment of 
ECP or immunoglobulin for therapy of EVD and are consistent 
with results of the Ebola-Tx trial [11, 12]. In the present study, 
EBOV viral load levels were assessed approximately 4 hours 
following the end of ECP infusion and daily to assess kinetics 
of any neutralizing activity. The reduced viral load at the first 
postinfusion time point in the 2 high-dose participants, but re-
bound at later time points, suggests that sampling for viral load 
at time points proximate to the end of ECP infusion may be in-
formative in future studies. We note that since our expression of 
viral load as GE was based on validation curves of the RT-PCR 
assay and the RT-PCR assay as performed at LIBR did not in-
clude an extraction control or standard curve, the absolute GE 
reported in this study should be considered an estimate.
The impact of ECP treatment on clinical outcomes cannot be 
assessed from these data, given the small number of participants 
and the severity of their disease, limitations also encountered in 
other EVD treatment trials [13–15]. Overall, participants in this 
trial comprised a group with predicted high mortality based on 
virologic, clinical laboratory, and clinical criteria [16–20].
The study’s strengths include careful assessment of Ebola 




































Figure 3. A and B, Ebola virus (EBOV) load in control participants. Participants 
were treated with enhanced standard of care. Blood specimens obtained at the 
time points indicated (squares) were assayed for EBOV by reverse-transcription 
polymerase chain reaction and converted to log10 genomic equivalents per mil-
liliter by a formula established at assay validation. Dashed line indicates lower 






































































Figure 2. A–D, Ebola virus (EBOV) load in participants treated with Ebola con-
valescent plasma. Participants were treated with enhanced standard of care. In 
addition, Ebola convalescent plasma was infused (vertical lines) within 4 hours 
after collection of preinfusion blood specimens for viral load. Specimens obtained 
at the time points indicated (squares) were assayed for EBOV by reverse-transcrip-
tion polymerase chain reaction and converted to log10 genomic equivalents/mL by 
a formula established at assay validation. Dashed line indicates lower limit of virus 
detection. Zero hours indicates time of first preinfusion specimen collection.
characterization of the potential potency of the ECP collected 
and administered. The trial also identified opportunities for 
enhancement to protocol design that could inform future trials 
of ECP efficacy. Had the anti-EBOV levels in donor ECP been 
available prior to treatment, ECP with higher antibody titers 
may have provided a better assessment of the effects of ECP 
on viremia. Donors with high anti-EBOV titers have now been 
identified in Liberia and other Ebola-affected countries, and 
have provided sufficient ECP to support further investigation 
should another outbreak occur in the near future. The excel-
lent sensitivity and specificity of the ELISAs for predicting neu-
tralizing activity reported here suggest that either of these tests 
could be used to screen donors to provide additional high-titer 
ECP in future trials.
We infused 200 mL of ECP (100 mL from each of 2 donors) 
at each dose, an amount that could be prepared by centrifuga-
tion from a single whole blood unit, as used by Mupapa et al [7]. 
A larger dose of ECP, as used in the Ebola-Tx trial with no appar-
ent adverse effects [12], may be advisable in future trials. Similarly, 
consistent treatment with 3 doses rather than allowing for omis-
sion of the third scheduled dose based on clinical improvement 
may be advisable in a future study to increase the number of 
data points and prolong the active treatment period. Data from 
NHP studies suggest that repetitive administration of antibody 
in the form of immunoglobulin is important for successful treat-
ment [21]; a series of 3 infusions was used in the Partnership for 
Research on Ebola Virus in Liberia II trial [14] of anti-EBOV 
monoclonal antibody cocktail. Convalescent whole blood from 
NHPs [22] and serum from humans [23] did not enhance survival 
of NHPs challenged with 1000 plaque-forming units of EBOV, 
which routinely leads to death 8–9 days after exposure.
In conclusion, this study showed that 7%–15% of EVD survi-
vors who planned to donate convalescent plasma were negative 
by 4 tests for anti-EBOV antibody. Further studies are needed to 
assess the frequency of antibody negativity in the overall survivor 
population and to evaluate innate and cellular immune responses 
that may mediate recovery in the absence of detectable antibod-
ies. Minimum thresholds for positivity in the EBOV or EBOV 
GP ELISA may be useful to predict the presence of plasma virus 
neutralizing activity and select ECP donors for further clinical tri-
als. A temporally related decline in plasma EBOV load following 
treatment with ECP containing neutralizing antibody observed in 
this study supports previous observations and justifies further eval-
uation of this intervention. The selection of ECP units with high 
anti-EBOV titers, use of a larger dose volume of ECP, administra-
tion of at least 3 repeated doses of ECP unless contraindicated, and 
frequent sampling for viral load in both controls and ECP-treated 
participants should be considered in the design of future trials.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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